Facial Skin Clinical and Microbial Profiling From Oral Probiotic Supplementation

The goal of this double-blind randomized clinical trial is to investigate the effects on the skin from oral intake of probiotic supplements in healthy adult men and women. The main questions it aims to answer are: • Will probiotic supplementation result in beneficial changes to different skin parameters? • Will probiotic supplementation result in alterations in the skin microbiome? Participants will consume the study product daily for 8 weeks and come in for skin measurements at baseline and after 8 weeks.

Study Overview

• Status: Completed
• Conditions: Healthy; Skin Manifestations
• Intervention / Treatment: Dietary supplement: Probiotic with niacin and berry extract; Dietary supplement: Probiotic without niacin and berry extract; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Actual): 109
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden, 11226
    • Oriflame Cosmetics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy volunteers
• Fully informed with the study specifications.
• Signed consent form prior to commencing the study.
• Motivated for participation in the study, and available over the full test period.
• Healthy skin on the face (i.e., absence of psoriasis, eczemas, erythema, oedema, scars, wounds, lesions, or any other type of inflammatory or autoimmune skin condition).
• Healthy gut (i.e., absence of irritable bowel diseases (IBD), irritable bowel syndrome (IBS), or any other type of inflammatory or autoimmune gut condition).
• No supplementation with probiotic, prebiotic or synbiotic products 2 weeks prior and/or during the whole study period.
• No supplementation with niacin (vitamin B3) 2 weeks prior and/or during the whole study period.
• No significant change in skin care routine (such as injectable cosmetics, skin tanning, etc.) throughout the whole study period.
• No significant change in the diet throughout the whole study period.

Exclusion Criteria:

• Not fulfilling the inclusion criteria.
• Pregnant or lactating 3 months prior to study commencement or during the study.
• Women post menopause.
• Use of antibiotics at least 4 weeks prior and/or during the whole study period.
• Sun-tanned facial skin.
• Participating in another clinical study that could interfere with the present research.
• Presented health problems or specific medications that could adversely affect the study outcome.
• Presented any cutaneous hypersensitivity or allergy to cosmetic products.
• Major surgery on the face one year prior to study commencement.
• Applied any cleansing, topical or moisturizing product (including all make-up products) to the measurement area the morning of assessments at Oriflame Cosmetic AB.
• Exposure to artificial UV light and/or to the sun during the study.
• Special diets (vegan, low carbohydrate, weight loss diet, etc.).
• Significant change in weight one month before or during the study period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Dietary supplement: Placebo; 1 capsule daily of placebo supplementation for 8 weeks
Experimental: Probiotic with niacin and berry extract	Dietary supplement: Probiotic with niacin and berry extract; 1 capsule daily of probiotic with niacin supplementation for 8 weeks
Active Comparator: Probiotic without niacin and berry extract	Dietary supplement: Probiotic without niacin and berry extract; 1 capsule daily of probiotic without niacin supplementation for 8 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline Skin Features (pores, wrinkles, colour, pigmentation and redness) at 8 weeks	Skin features: Pores, wrinkles, colour, pigmentation and redness Site: Cheek, Temple and Forehead - 3 measurement per area. Thus 9 in total. Procedure: As per WI091 Standard use of the Miravex Antera 3D Camera V1 and TM089 Skin features measurements Using the Antera 3D V1 Unit: Pores: volume (mm3), index, count, volume/count Wrinkles: overall size, depth (mm), width (mm), Texture: Average Roughness (Ra) Colour variation: DeltaE Pigmentation/redness: average level (concentration per unit area), color variation.	Day 0, Day 56
Change from Baseline Skin Features (shininess) at 8 weeks	Skin features: Shininess Site: Entire face Procedure: As per WI044 Standard use of the VISIA-CR2.2 V3 and TM066 Determination Of Skin Brightness Using The Image Pro Plus Shine Macro Test V2 Unit: Arbitrary unit (AU)	Day 0, Day 56
Change from Baseline Skin Features (spot size and color) at 8 weeks	Skin features: Spot size and color Site: Entire face Procedure: As per WI044 Standard use of the VISIA-CR2.2 V3 and TM038 Clinical Determination of Spot Size and Colour Unit: Color = L*a*b*, Delta E Spot size: volume, count	Day 0, Day 56
Change from Baseline Superficial Hydration at 8 weeks	Skin feature: Superficial hydration Site: Upper cheek - triplicate measurements Procedure: As per WI003 Standard use of the Corneometer CM 825 to measure skin moisture V4. Unit: Arbitrary unit (AU)	Day 0, Day 56
Change from Baseline Skin Barrier Integrity at 8 weeks	Skin feature: Skin barrier integrity Site: Upper cheek - single measurement Procedure: As per WI094 Standard Use of the Delfin Vapometer for Skin Barrier Measurements V1. Unit: g/m2h	Day 0, Day 56
Change from Baseline Sebum Level at 8 weeks	Skin feature: Sebum level Site: Forehead - triplicate measurements Procedure: As per WI005 Standard use of the Sebumeter SM 815 & MPA 5 to Measure Skin Sebum Levels V2. Unit: µg/cm2	Day 0, Day 56
Change from Baseline Antioxidant Level at 8 weeks	Skin feature: Antioxidant level Site: Temple/Cheek area Procedure: BioZoom Unit: Arbitrary unit (AU)	Day 0, Day 56
Change from Baseline Microbial Level at 8 weeks	Skin feature: Microbial Level Site: Forehead Procedure: Damp cotton swab Unit: Microbial count by sequencing	Day 0, Day 56

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Questionnaire on general health and wellbeing	Subjective measurements of self-rated health aspects using a 9-point hedonic scale (extremely good to extremely bad) at baseline, mid and end of study to access intervention effects	Day 0, Day 28, Day 56

Collaborators and Investigators

• Sponsor: Oriflame Cosmetics AB
• Investigators: Principal Investigator: Isabella Lee, Global Senior Nutritional Scientist

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2022
• Primary Completion (Actual): December 9, 2022
• Study Completion (Actual): December 9, 2022

Study Registration Dates

• First Submitted: October 11, 2022
• First Submitted That Met QC Criteria: October 26, 2022
• First Posted (Actual): October 28, 2022

Study Record Updates

• Last Update Posted (Actual): May 1, 2023
• Last Update Submitted That Met QC Criteria: April 28, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Manifestations; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Antimetabolites; Micronutrients; Hypolipidemic Agents; Lipid Regulating Agents; Vitamins; Vitamin B Complex; Nicotinic Acids; Niacinamide; Niacin
• Other Study ID Numbers: 2022-00672-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No